EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access

Rituximab as monotherapy and in combination with methotrexate or leflunomide in rheumatoid arthritis: a prospective cohort study in a Peruvian hospital

Freddy Liñán-Ponce iD, Juan Leiva-Goicochea iD, Fernando Gross-Melo iD

Rheumatology · 27.02.2026 · 64 (1) · 4-10

DOI: 10.5114/reum/213648 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Rheumatology, online erschienen am 27.02.2026. Verfasst von Freddy Liñán-Ponce und 2 weiteren Autor:innen. Beteiligte Einrichtung: Victor Lazarte Echegaray Hospital, Trujillo, Peru. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Rheumatoid arthritis (RA) is an autoimmune disease whose treatment has evolved with the introduction of disease-modifying antirheumatic drugs and biological agents such as ritu­ximab (RTX). The objective of this study was to evaluate the efficacy, safety, and treatment adherence of RTX used as monotherapy and in combination with methotrexate (MTX) or leflu­nomide (LFN) in patients with RA refractory to conventional therapy. Material and methods A prospective cohort study was conducted including 157 patients, divided into 3 groups: RTX monotherapy (n = 48), RTX + MTX (n = 66), and RTX + LFN (n = 43). Efficacy, safety, and adherence were evaluated at weeks 1, 24, and 48 using the Health Assessment Questionnaire (HAQ), Disease Activity Score in 28 joints (DAS28), American College of Rheumatology 70% response (ACR70), and Treat-to-Target (T2T) criteria. Ethical approval was obtained from the local institutional ethics committee.

Results

All 3 therapeutic regimens demonstrated comparable clinical efficacy, with no statistically significant differences in disease activity scores. Adverse events were more frequent in the RTX + LFN group, although not statistically significant. Treatment adherence was highest in the RTX monothe­rapy group (100%).

Conclusions

No significant differences in efficacy or safety were found among the 3 study groups; However, treatment adherence was significantly higher in the RTX monotherapy group (100%).

Schlagwörter

Stichwörter der Autor:innen

leflunomidemethotrexaterheumatoid arthritisrituximab

Autor:innen und Institutionen

  • Victor Lazarte Echegaray Hospital, Trujillo, Peru.

ORCID-Profile: Freddy Liñán-Ponce, Juan Leiva-Goicochea, Fernando Gross-Melo

Zitieren

APA

Liñán-Ponce, F., Leiva-Goicochea, J., & Gross-Melo, F. (2026). Rituximab as monotherapy and in combination with methotrexate or leflunomide in rheumatoid arthritis: a prospective cohort study in a Peruvian hospital. Rheumatology, 64(1), 4-10. https://doi.org/10.5114/reum/213648

Vancouver

Liñán-Ponce F, Leiva-Goicochea J, Gross-Melo F. Rituximab as monotherapy and in combination with methotrexate or leflunomide in rheumatoid arthritis: a prospective cohort study in a Peruvian hospital. Rheumatology. 2026;64(1):4-10. doi:10.5114/reum/213648

BibTeX
@article{LinPonce2026,
  author = {Liñán-Ponce, Freddy and Leiva-Goicochea, Juan and Gross-Melo, Fernando},
  title = {Rituximab as monotherapy and in combination with methotrexate or leflunomide in rheumatoid arthritis: a prospective cohort study in a Peruvian hospital},
  journal = {Rheumatology},
  year = {2026},
  volume = {64},
  number = {1},
  pages = {4--10},
  doi = {10.5114/reum/213648}
}
Kostenlos starten →